Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 13%
Buy 25%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is demonstrating a robust financial outlook, with a significant 10-11% year-over-year expected growth in US pump shipments and a noted 7% contribution from pharmacy channel revenue, which doubled sequentially. The revenue forecasts for 2026 and 2027 reflect steady increases, with a slight revision to $1.111 billion and $1.229 billion respectively, indicating ongoing strong demand and market penetration. Additionally, positive trends in new patient starts, driven by increased access to affordable pharmacy options and a growing installed base, support an optimistic trajectory for the company’s revenue growth.

Bears say

Tandem Diabetes Care has experienced significant operating losses since its inception and is projected to sustain a negative EBITDA of between -2% and -1% of revenue, indicating ongoing financial challenges. Revenue estimates for 2026 have been reduced to $1.07 billion, with US sales guidance reflecting a headwind of approximately $70 to $80 million due to Pay-Go pump shipments, alongside an anticipated decrease in new patient starts. Risks associated with increased competition, limited traction from new product launches, and the failure of the Mobi launch to generate profit could further hinder the company's ability to achieve sustainable growth and profitability.

TNDM has been analyzed by 16 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 25% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Hold based on their latest research and market trends.

According to 16 analysts, TNDM has a Hold consensus rating as of Mar 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.